• Infant Bacterial Therapeutics completed commercial-scale manufacturing validation for IBP-9414 with positive results in the third quarter of 2026.
• An October 29 FDA pre-BLA meeting identified no obstacles to submitting a Biologics License Application for the drug candidate.
• The Phase III Connection study, completed in July 2024, showed a 27% reduction in all-cause mortality versus placebo in premature infants.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Infant Bacterial Therapeutics AB published the original content used to generate this news brief on November 13, 2026, and is solely responsible for the information contained therein.